The concomitant use of buprenorphine and CYP3A4 inducers can decrease the plasma concentration of buprenorphine [see CLINICAL PHARMACOLOGY], potentially resulting in lowered efficacy or onset of the withdrawal syndrome in people who have made Bodily dependence to buprenorphine.The approximated background risks of big start defects and miscarriage t